Author Archives: admin


INTERNATIONAL REGENERATIVE MEDICINE COMMUNITY TO … – EconoTimes

INTERNATIONAL REGENERATIVE MEDICINE COMMUNITY TO CONVENE FOR 13TH WORLD STEM CELL SUMMIT IN MIAMI, JANUARY 2018

The 13ththWorld Stem Cell Summit http://www.worldstemcellsummit.com is taking place January 23-26, 2018 at the Hyatt Regency Miami. Produced by the nonprofit Regenerative Medicine Foundation (RMF), the event is the global ecosystem meeting for advanced therapies; fostering public understanding, promoting positive policy initiatives and collaborations.

The World Stem Cell Summit will be co-located with the fields premier industry partnering event, Phacilitate Leaders Forum, Cell & Gene Therapy World and Immunotherapy World.

In addition to compelling keynotes, plenary and focus sessions, thediverse four-day program includesexpert lunch roundtables; a centrally located Expo packed with innovators in industry, academia and government; a poster forum showcasing science and policy research; the galaStem Cell Action Awards Dinnerhttp://regmedfoundation.org/awards/; as well as many exclusive networking and partnering opportunities.

RMF Executive Director Bernard Siegel, founder and co-chair of the Summit said, We are proud to select Miami to be our host for the next World Stem Cell Summit. Miami is often referred to as the 'City of the Future' and in 2018 it will be the center of the stem cell universe. Its the perfect venue for Summit attendees to gain knowledge, network and collect opportunities to advance their goals, in a superlative, cosmopolitan setting.

ABOUT RMFRegenerative Medicine Foundation is dedicated to accelerating regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honoring leaders through the Stem Cell Action Awards http://worldstemcellsummit.com/stem-cell-action-awards/, publishing the World Stem Cell Report and RegMed Newsletter, organizing educational initiatives such as the upcoming Regenerative Medicine Essentials Course http://www.wakehealth.edu/Research/WFIRM/RMEssentials/Regenerative-Medicine-Essentials.htm and fostering strategic collaborations.

For more information about RMF, visitwww.regmedfoundation.orgor contact Bernard Siegel directly at Bernard@regmedfoundation.org.

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/64ef8cd8-84a3-4130-8a8f-f1e020eaeba3

Human Life Could Be Extended Indefinitely, Study Suggests

Goosebumps, tears and tenderness: what it means to be moved

Are over-the-counter painkillers a waste of money?

Does an anomaly in the Earth's magnetic field portend a coming pole reversal?

Immunotherapy: Training the body to fight cancer

Do vegetarians live longer? Probably, but not because they're vegetarian

Could a contraceptive app be as good as the pill?

Some scientific explanations for alien abduction that aren't so out of this world

Society actually does want policies that benefit future generations

Six cosmic catastrophes that could wipe out life on Earth

Big Pharma Starts Using Cannabis For Making Drugs In Earnest

Do you need to worry if your baby has a flat head?

See the original post here:
INTERNATIONAL REGENERATIVE MEDICINE COMMUNITY TO ... - EconoTimes

Mixing Music and Medicine: Meet Grammy-Nominated Producer Nana Kwabena – NBCNews.com

Grammy award winning recording artist Bilal with his son Ramzee, who suffers from Sickle Cell, at Sickle Cell Thalassemia Patients Network (SCTPN) in Brooklyn, NY. Karole Collier

Before getting into music professionally, you were actually on the path to a very different career in the medical field. What brought about the change in your career path?

Nana Kwabena: I don't come from a musical family. I was actually raised to become a doctor and I was pre-med in college. That was the path that my parents wanted me to take. As much as my parents pushed me down this path, my mom knew that I was going to be a musician. They were all just in denial about it because being a musician was taboo as a first-gen Ghanaian-American.

I went through school with two different lives. On one hand I'm studying to become a doctor with the idea of using that expertise to treat sickle cell disease by day, but then by night I was living a whole different life. I would be in Philly and have about 30 different Philly rappers in the room, their own Wu-Tang if you will, and I'm producing beats and then I have to say alright guys it's six in the morning and I'm going to get an hour of sleep and then go take organic chemistry.

Related:

I remember graduating from UPenn [University of Pennsylvania] and thinking that these two things are getting too big and something's got to give. I never quite knew how to make them work in concert with each other, so what do you do? You buy time.

I deferred my acceptance to George Washington University, to the Milken School of Public Health with the hopes of making it in music. I moved to New York and gave myself a year with the idea that if that didn't work out, I was going to go back and continue pursuing the medical field. In my first year in New York I wrote a song with John Legend and thought maybe I should continue.

In 2011, when you were just starting off in the music industry, you lost your younger brother Kwame to sickle cell disease. How did that experience mobilize you to bring your background in the medical field and music together in order to raise awareness about the disease?

All of a sudden these two halves of my life (music and medicine) that always felt in conflict with each other, once my brother passed they became one. They became the yin and yang to each other. Music and the medicine. Music was the medicine. So out of that I created a non- profit called AllOneBlood with the idea to change the conversation around sickle cell disease.

Related:

My brother Kwame had conviction and he had passion and that was always his default and it didn't matter who you were. He was just always unapologetic about his own light and what he believed in. So when he passed I think that I inherited that idea of really just being able to be audacious, regardless of what people think you're supposed to be or the limitations you may have.

Death really, really clarifies things. It puts life in perspective. It gave me the ability to realize that sickle cell did not have to be a forgotten disease and we could educate people and rally around the cause for a cure.

As someone who suffers from sickle cell disease, what would you say are some of the major misconceptions that people have about it? How is your organization AllOneBlood working to help change that?

I think sickle cell is a disease that within the context of America feels like a black disease, or it only affects black people and because of that it kind of becomes a disease that gets less attention. There are diseases that affect far less people in number and have ten times the budget for their national organizations.

I think there are a lot of misconceptions around the disease or thoughts around the disease that make people feel like if they don't suffer from it, then they can't support it. There are many faces to sickle cell disease and a lot of people don't know that. What AllOneBlood tries to do is kind of just change the conversation around the disease and kind of open up the spectrum to show that on a global level when you remove this national lens you see that it affects people of all races.

There's also this stigma with chronic disease where we feel like when you have these things you have to hide it. I studied abroad in Ghana while in college and I did a research study looking at elementary aged children that had sickle cell disease and whether or not they disclosed or concealed having the disease.

There were many kids that had sickle cell disease and they would endure sickle cell pain crisis, which are like terrible, awful pain attacks. It's the kind of pain that I have had as an adult and have been screaming to the top of my lungs, so imagine a kid dealing with this. These children would be at home having that level of pain and would go into a closet in their bedroom and close the door where they would stay and sob, not telling their parents. Why? It was because they didn't want to go to the hospital and miss school the next day and have people say oh that person missing might be a 'sickler'.

I wanted the conversation around the disease to go beyond the notion that this is something that is debilitating or that this is something that cripples us and it be looked at as a feature. I decided that I would let everyone and anyone know that I have sickle cell. When you can be in tune with the things that make you different it actually makes you stronger. It makes you powerful.

In your opinion, what role can music play in creating change and what responsibility do music and musicians have to use their art to effect change?

Music is one of the biggest and easiest and most effective ways to connect people that would otherwise not be connected to each other.

I've always appreciated artists' who made art that wasn't just art for art's sake. It was art that actually had real tangible impact on people's lives. I grew up listening to Bob Marley, Michael Jackson, Fela Kuti and Tupac. These were people for me that if you only made the rubric about creatives then they were the best. But, if you also open up the rubric and judge them in terms of the real impact they had on the world, these are people whose music shifted the entire world.

That's what I want to use music for. I don't want to just use music to be someone that's like, yeah we'll just make dope beats and have fun and it will be an escape to the harsh realities of the world.

I want it to be a tool that deals with the harsh realities of the world. That to me is the motto that I live by and I've always loved the ability music has to have that kind of influence.

It's actually bigger than music, but the music is a very strong vehicle to help effect real change in people's lives. And, I've had the pleasure of working with not only creative people and really talented people in that way, but some of the best and greatest spirits of our generation as well.

What are some things you do that you help manage sickle cell disease and what keeps you motivated?

Your general health and general well-being has a large effect on how you deal with sickle cell and whether or not you have attacks. Your nutrition is the biggest thing. If you can have a healthy diet and stay away from too much processed food as well as properly hydrate yourself and also exercise, it is so important. These are some of the things that I do. Being in a positive mental space is also extremely important.

Related:

Although there are some limitations due to sickle cell disease I encourage those who also have the disease to push themselves to live a wholesome life and not allow it to be something that stops your from living your dreams or simply living.

What keeps me motivated is being around people and finding inspiration that keeps that torch inside of me fueled. To not feel anything at all is a dangerous thing and I spend most of my life trying to guard my own fire, protect my fire and then add to that fire.

John Legend visiting the Sickle Cell Pediatrics unit at the Children's Hospital Los Angeles with AllOneBlood. He spent time and spoke with the kids who were getting treatment, surprising them with a performance in between rounds of treatment and therapy. Corwin Levi

What is the progress you have seen in terms of awareness and education about sickle cell since you started AllOneBlood in 2012?

I think that there have been tremendous strides made recently where there are treatments that could cure the disease, but not a lot of people know about them. However, the beauty of this is that the disease is actually curable in within our lifetime.

AllOneBlood partnered Universityof Illinois Medical School, where doctors recently cured sickle cell disease in 16 of 19 patients without using traditional chemotherapy in 2016. This year, we're working to raise funds so that more families who qualify for the treatment can be covered in addition to helping families across the country with other care related expenses.

My goal is to make it (a cure) a reality and that's what my life is dedicated to. My life is literally using music as the vehicle to cure sickle cell disease off the planet. I really have two goals that's one of them. The second is building the bridges throughout the African diaspora.

I'm Ghanaian-American and I really have this belief that Africa has this desire for all of its children to be able to recognize Africa no matter the time goes by. Africa has been erased and has been consistently been erased from history of its contributions to the entire world. My life is about making sure that it gets the recognition that it deserves.

Nana Kwabena Oz Shaw

What's next for AllOneBlood and what can we expect from you as far as new music projects this year?

We are working on our inaugural fundraiser gala where we will bring all our partners together to share information and enjoy performances that will contribute to making a difference. Right now we are in the planning phases of that and we really look forward to that. That's what's next for AllOneBlood in particular.

Outside of that, creatively, more music is on the way. I'm working on a couple of projects. Janelle's getting ready to drop what I actually believe is going to be her best album, which I've had the pleasure of being involved with. Jidenna and I are working on album two, there's also a short film. There's a lot going on, but I'm just trying to live the most fully expressed life and be on the highest vibration as long as I possibly can.

For more information on the non-profit All One Blood, please visit

Follow NBCBLK on

Originally posted here:
Mixing Music and Medicine: Meet Grammy-Nominated Producer Nana Kwabena - NBCNews.com

Stem cell vaccine found to increase immune responses, inhibit tumors in animal models – Medical Xpress

May 10, 2017 John Morris, M.D. Credit: University of Cincinnati

Researchers at the University of Cincinnati (UC) have found that a cancer stem cell vaccine, engineered to express a pro-inflammatory protein called interleukin-15 (IL-15) and its receptor (IL-15Ralpha), caused T cell production in animal models and enhanced immune responses against tumors.

This T cell production showed a cellular immune response that could lead to new immunotherapy treatments for cancer with improved side effects.

These findings are being presented via poster abstract at the American Society of Gene and Cell Therapy's annual meeting in Washington, D.C., May 10-13.

"IL-15 is a powerful stimulator of the maturation and activation of T cells and natural killer cells that recognize and attack tumor cells. Human IL-15 was first used in Phase I clinical trials to test its efficacy for treatment of a number of cancers, including melanoma and kidney cancer, but caused a number of side effects that made high doses difficult for patients to tolerate," says John Morris, MD, co-author of this study, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the Cincinnati Cancer Consortium, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the Division of Hematology Oncology at the UC College of Medicine and UC Health medical oncologist. "In this work, we showed that transferring the genes for both IL-15 with its receptor into cancer cells increased the cell-surface presentation of IL-15 to T cells, and in turn, stopped the tumor cells from reproducing with little evidence of side effects in animal models.

"In an effort to enhance antitumor activity and reduce side effects, we studied a vaccine targeting cancer stem cells, the cells in a tumor thought to be resistant that give rise to recurrent tumors after treatment, by genetically altering them to express IL-15 and IL-15Ralpha to see if lung cancers implanted in animal models shrunk."

Using animal models and their lung cancer cell lines, researchers introduced the IL-15/IL-15Ralpha-modified lung cancer stem cells as a vaccine and saw dramatically reduced tumor growth.

"Animal lung cancer stem cells expressing IL-15 and IL-15Ralpha stimulated proliferation of T cells suggesting the ability to enhance immune responses," he says. "These findings further support evidence of IL-15's ability as a cancer treatment. We are continuing vaccination studies in animal models with hopes of moving this research to a Phase I trial in humans to see if side effects are reduced."

Explore further: Cancer vaccine could use immune system to fight tumors

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Glioblastoma is the most common brain tumor in humans and also one of the most difficult cancers to treat; patients with this type of cancer only survive about one year from time of diagnosis. Researchers at Baylor College ...

UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or ...

Researchers at the Cincinnati Cancer Center (CCC) and theUC Cancer Institute are conducting a clinical trial examining a method to stimulate the human immune system to destroy or block the growth of lung cancer cells.

Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association ...

Many cancer patients, especially those who've undergone breast cancer treatment, experience painful, swollen limbs, a condition called lymphedema.

Among today's most promising weapons against cancer is the use of therapies that direct the immune system against a tumor. One approach - immune checkpoint blockade - is designed to circumvent the "off switches" that prevent ...

Lung adenocarcinoma, an aggressive form of cancer that accounts for about 40 percent of U.S. lung cancer cases, is believed to arise from benign tumors known as adenomas.

UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.

Researchers at the University of Cincinnati (UC) have found that a cancer stem cell vaccine, engineered to express a pro-inflammatory protein called interleukin-15 (IL-15) and its receptor (IL-15Ralpha), caused T cell production ...

In the largest genomics study of clear cell endometrial cancer (CCEC) tumors to date, National Human Genome Research Institute (NHGRI) researchers and their collaborators have identified mutations in the TAF1 gene. They've ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Originally posted here:
Stem cell vaccine found to increase immune responses, inhibit tumors in animal models - Medical Xpress

Adaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell Therapy Targeting AFP in Liver Cancer – StreetInsider.com

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular carcinoma, the sixth most common cancer worldwide. This study is now open for enrollment.

This is Adaptimmunes second wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapy targeting the MAGE-A10 cancer antigen in patients with non-small cell lung cancer, urothelial cancer, melanoma, or head and neck cancers.

We are excited to initiate this study to evaluate our AFP T-cell therapeutic candidate in patients with hepatocellular carcinoma, said Rafael Amado, Adaptimmunes Chief Medical Officer. HCC is one of the more common and deadly types of cancer worldwide and there is an urgent need for effective therapies for advanced disease.

This is a Phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity of Adaptimmunes alpha fetoprotein (AFP) therapeutic candidate in hepatocellular carcinoma (HCC). The study will enroll up to 30 patients with measurable, histologically confirmed HCC, not amenable to resection or loco-regional therapy, and with progressive disease. The primary objective of the study is to evaluate the safety and tolerability of this second-line therapy (post-sorafenib) in patients with AFP-positive HCC. Additional objectives include anti-tumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion.

Additional information about this study is available at http://www.clinicaltrials.gov by searching on NCT03132792.

Continued here:
Adaptimmune Therapeutics (ADAP) Begins Study on SPEAR T-Cell Therapy Targeting AFP in Liver Cancer - StreetInsider.com

AJ Foyt on fear, his stem cell therapy and more – Indianapolis Star

The Indy 500 legend has been through several highs and lows recently. Clark Wade/IndyStar

Indianapolis 500 legend A.J. Foyt.(Photo: Clark Wade/IndyStar)Buy Photo

Its been a long and wild ride, and A.J. Foyt has enjoyed nearly every second of it.

I had a lot of fun, the 82-year-old racing legend told IndyStar on Wednesday at his racing garage in Speedway. If I passed out talking to you right now and fell on the floor, at least I made good money, had a happy life and what else can you ask for? So many people are so miserable with their jobs and that. I had a wonderful job doing what was fun.

Foyts job driving into racing's history books provided him with a lifetimes worth of close friends, amazing stories and thrilling adventures. But it also often required him to put his life on the line.

"I guess I was a little bit crazy back in those days,"Foyt, who walks with a limp but without assistance, said with a smile.

But being crazy was part of the job, he said. He needed it to overcome his fears.

"A lot of race drivers you talk to these days say they've never been scared in racing," Foyt said. "Well, they're lying to you and they're lying to themselves. I cannot name you one race at one time or another thatI didn'tscare the hellout of myself. Honestly. I don't know if that's good or bad, but I'm just being honest with you."

Read more from Jim: Alexander Rossi is starting to feel at home in Indy

This year's Indy 500 crowd is on pace to pass 300,000

Despite thosehealthy fears, his long and prestigious racing career resulted ina laundry list of injuries and eventual ailments that would and have horrifieddoctors.

The four-time Indianapolis 500 champion has stared death and dismemberment in the face more times than hed care to count, dealing withcar wrecks, killer bees, a bulldozer accident, heart ailments and two staph infections. As a result, hes nearly had his feet amputated,broken his back two or three times, has two false knees and a false hip, a titanium plate in his chest from open heart surgeryand said hell be on antibiotics for the rest of his life because of the amount of metal he has inside of him.

But he's far from discouraged and fightsto keep going with the same vigor and courage the colored his youth. One way he's done so recently is by undergoing stem cell therapy.Foyt said his wife, Lucy, who suffers from diabetes and arthritis, suggested that they both take on the treatment in order to try and find "the fountain of youth."

I mainly did it for her, Foyt said. She got sugar diabetes real bad, and (is) pretty sick, but, of course, I did it for myself too, dont get me wrong. But shes really been suffering the last five or six years. So we just thought wed try it.

A.J. and Lucy Foyt spent seven days in Cancun, Mexico the treatment is not performed in the United States undergoing a therapy he said likely wont take effect for another month at least. A.J. Foyt had adult stem cells injected into each shoulder and ankle, as well as into his blood.

Theres no guarantees the treatment will help either of them, but the uncertainty doesnt bother him.

I figure if we gain something, fine, and if we dont, well, Ive lost before," Foyt said.

But giving Foyt an edge in his fight against injury, ailment and Father Timeis a competitive fire that has burned within him his whole life.

A little more than a month ago, Foyt and fellow driving legend Dan Gurney were honored in Long Beach, Calif., for the 50th anniversary of their all-American victory at 24 Hours of Le Mans. Many racing greats attended the event, and Foyt was happy to see them, but he couldn't help but stackhimself up one more time against his old rivals.

I guess Im doing better than them, Foyt said with a smile. Poor Parnelli (Jones) has a lot of back trouble. Dan was in a wheelchair. Last three or four years Ive been going in and out of them, but Im still going pretty strong. So far Im hanging in there pretty good. ...Every days a good day. And Iguess thats good when youre getting ready to kick."

Follow IndyStar Motor Sports Insider Jim Ayello on Twitter and Instagram: @jimayello.

Autoplay

Show Thumbnails

Show Captions

See the article here:
AJ Foyt on fear, his stem cell therapy and more - Indianapolis Star

A trade in desperation: The rise of stem cell tourism – Pursuit

Republish this article

We believe in the free flow of information. This work is licensed under a Creative Commons Attribution-No Derivatives 3.0 Australia (CC BY-ND 3.0 AU), so you can republish our articles for free, online or in print.

All republished articles must be attributed in the following way and contain links to both the site and original article: This article was first published on Pursuit. Read the original article.

Associate Professor Megan Munsie, Dr Casimir MacGregor, Dr Claire Tanner, Jane Brophy and Professor Alan Petersen

In Australia, in recent years, there have been a number of news reports of patients and carers travelling overseas for stem cell treatments. Their journeys are part of a wider international trend, commonly referred to as stem cell tourism, whereby patients and their carers travel across geographical borders and jurisdictions to receive treatments that are experimental or clinically unproven, and hence, may not be available to them where they live.

The stories features in the news are often framed within a now-familiar narrativedesperate patients full of hope investing in treatments that promise much, and scientists and doctors voicing frustrations about entrepreneurial charlatans or cowboys operating at the margins of medicine and exploiting regulatory loopholes to sell snake oil.

Why, authorities ask, do patients and carers embark on such treatments that are unlikely to provide benefit, are expensive, and potentially in inflict great harm?

By their accounts, patients and carers tended to embark on the search for information, about the condition itself and about treatment options, very soon after diagnosis, and often in the absence of definitive expert advice.

Ivan, a father-carer of a child with cerebral palsy, articulated a commonly expressed view; namely, that no one gave us any real direction so we sort of had to do all the research ourselves.

Research can be long and tortuous, spanning in some cases a period of years, and take individuals and their families down numerous avenues, and sometimes blind alleys. Their post-diagnostic experience is thus in many respects similar to that of other patients, such as those suffering genetic conditions, long reported in the literature.

However, the rise of the internet and social media, along with the burgeoning number of online resources, has radically changed the architecture of choice. During their investigations, patients and carers encounter an array of online resources, found primarily via search engines such as Google, and information provided by disease-specific patient communities, individual patients and their families, as well as information offered by providers on their websites.

A number mentioned the importance of Facebook for sharing information, and YouTube videos and blogs for finding relevant sources. Through these avenues, and invariably after being advised of their limited options by their treating doctors after diagnosis, individuals soon came to the realisation that their options for proven treatment in Australia were limited or non-existent.

The nature of the condition and the prognosis constrain options and the potential and urgency to pursue those that are available. Individuals who embark on a stem cell treatment are in most cases struggling with severe, life-limiting conditions (e.g. spinal cord injury, motor neurone disease, multiple sclerosis, cerebral palsy), some terminal and, for many, time is of the essence.

As one patient, Greg, with a progress degenerative neurological disease affecting movement, explained in relation to his decision to pursue stem cell treatment in China: If youre in a condition like mine or cancer ... you will try these sorts of things. If you havent got a condition like that you tend to be more sceptical.

As he reasoned, stem cell treatment seemed to have more going for it than the whole range of things out there and, as they were financially able to undertake treatment, Well, why not try it now while I can?.

At least in one case, an element of pragmatism played a role in the decision to undertake stem cell treatment. Parents of a child with cerebral palsy, Ivan and Vlasta, said they had explored and tried various therapies and hoped that stem cell therapy would offer something differenta sort of more attractive way of try and give him a little boostthereby obviating the need for intensive, time- consuming daily therapy. As they explained, Were very busy people and running [a] business, and we have very little time to ourselves. This pragmatism also appeared to be a factor in their decision to take their child for treatment in Germany and China.

In their search for options, some individuals experimented with diets and complementary and alternative therapies.

Two patientsa patient with multiple sclerosis and a mother-carer of a child with autismmentioned that their research had uncovered the role of nutrition, which had led them to exclude gluten and dairy from their diet, which they felt had resulted in improvements in health.

In the latter case, as in a number of others, stem cell treatment was seen as additional to rather than supplanting complementary and alternative therapiesas one of an array of options that was seen as worth exploring. For some participants, clinics that were offering treatment packages, which included a range of therapies beyond Western biomedicine (i.e. acupuncture, massage, traditional Chinese medicine) in addition to stem cells, were particularly attractive and influenced their decision of where to travel.

The lack of stem cell treatment options in Australia was often cited as being crucial in the decision to travel overseas. Many individuals commented or implied that stem cell treatment should have been available to them in Australia and, since it was not, they felt that they had no choice but to seek treatment overseas.

One carer, Donna, whose partner suffered a rare neurological condition, when asked about the benefits for people travelling overseas for stem cell treatments, responded: Well you cant get it here so you dont really have a choice. If you want to try it ... well you dont have a choice.

A patient who had spinal cord injury, Axel, expressed similar sentiments when explaining the treatment challenges confronting those in his community: If theres no treatment available in Australia now and there wont be for a long time ... weve got no choice but to go over- seas to get treatment in the future.

Indeed, some described feeling desperate about their situation, underlining the anguish that they experienced. As we explain, this sense of abandonment, loss of hope and/or desperation does not always lead to the decision to pursue treatment; however, for virtually all, this perceived hopelessness and limited options or no choice in Australia defined the context within which decisions were made.

Banner image: In Pictures Ltd./Corbis via Getty Images

This is an edited book extract from Stem Cell Tourism and the Political Economy of Hope whichis published by Palgrave Macmillan. More information is available here.

The Media Office is staffed from 8am5pm Monday to Friday.

The University has a television and radio studio to facilitate live and prerecorded broadcast quality interviews with media. You can also Find an expert for commentary.

See more here:
A trade in desperation: The rise of stem cell tourism - Pursuit

Hundreds of new stem cell lines ready to help research – The San Diego Union-Tribune

Induced pluripotent stem cells have revolutionized stem cell science in the decade since their invention. Theyre yielding clues into the nature of diseases such as cancer and Alzheimers, and are also being tapped for therapy.

But creating these IPS cells is lengthy, complicated and tricky, and the facilities equipped to make them cant accommodate all the scientists whod like to get their hands on them.

A UK-led consortium has removed that bottleneck, by producing 711 lines of ready-to-go IPS cells from healthy individuals. These lines are meant to help scientists understand the normal variations between healthy individuals and those involved in disease, as well as to understand normal human biology and development.

The IPS lines are available for research purposes to academic scientists and industry by contacting the Human Induced Pluripotent Stem Cell Initiative (HipSci), at http://www.hipsci.org and the European Bank for induced Pluripotent Stem Cells at https://www.ebisc.org.

The accomplishment was announced in a study published in Nature. It can be found online at j.mp/711ips.

While many other efforts have generated IPS cells to address rare diseases, this study produces them from healthy volunteers to plumb common genetic variation, Fiona Watt, a lead author on the paper and co-principal investigator of HipSci, from King's College London, said in a statement.

"We were able to show similar characteristics of iPS cells from the same person, and revealed that up to 46 per cent of the differences we saw in iPS cells were due to differences between individuals, Watt said in the statement. These data will allow researchers to put disease variations in context with healthy people."

Andrs Bratt-Leal, director of the Parkinson's Cell Therapy Program at The Scripps Research Institute in La Jolla, agreed.

This kind of study is extremely important because it leads to a deeper understanding of the differences between normal genetic variation and genetic changes that could negatively impact cell behavior, said Bratt-Leal, who was not involved in the study.

This data will help scientists using induced pluripotent stem cells to model diseases as well as scientists developing cell therapies, said Bratt-Leal, who works in the lab of stem cell researcher Jeanne Loring.

Because DNA sequencing has become a routine tool in the lab, enormous amounts of data have been produced, he said. Not only have we have observed a high level of genetic diversity between different people, but also a more subtle variation exists among the cells from an individual person. The next step is a better understanding of how this diversity translates to function and behavior of stem cells and mature cells derived from stem cells.

Loring and Bratt-Leal are studying the use of induced pluripotent stem cells to relieve symptoms of Parkinsons disease. They are in the process of translating the research into a therapy, aided with a grant from the California Institute for Regenerative Medicine.

The work was the product of a large-scale collaboration of scientists from various institutions in the United Kingdom, including the European Molecular Biology Laboratory in Cambridge; Wellcome Trust Sanger Institute in Cambridge; the University of Dundee in Dundee; and the University of Cambridge. Also participating was St Vincent's Institute of Medical Research in Victoria, Australia.

bradley.fikes@sduniontribune.com

(619) 293-1020

UPDATES:

1:00 p.m.: This article was updated with additional details.

This article was originally published at 10:00 a.m.

See the rest here:
Hundreds of new stem cell lines ready to help research - The San Diego Union-Tribune

Survival in MDS Equivalent With Reduced-Intensity Conditioning – Cancer Network

Patients with myelodysplastic syndrome (MDS) undergoing a reducedintensity conditioning (RIC) regimen prior to allogeneic stem-cell transplantation had similar 2-year relapse-free and overall survival as patients who underwent myeloablative conditioning (MAC), according to the results of the RICMAC trial.

The role of conditioning regimen intensity before allogeneic stem-cell transplantation for MDS has not been studied prospectively and recommendations are based on retrospective single-center or registry studies, wrote Nicolaus Krger, MD, department of stem cell transplantation, University Medical Center Hamburg-Eppendorf, and colleagues in a study published in the Journal of Clinical Oncology. The rationale for using RIC before allogeneic stem-cell transplantation is to shift from high-dose chemotherapy that is aimed at maximizing cytotoxic leukemia killing to a more immune-mediated effect by harvesting the graft-vs-tumor effect to eradicate the disease.

In this study, the researchers enrolled 129 patients with MDS or secondary acute myeloid leukemia and randomly assigned them 1:1 to a busulfan-based RIC or MAC.

At 1 year, the non-relapse mortality was 17% in patients assigned RIC compared with 25% in patients assigned MAC (P = .29). The cumulative incidence of relapse at 2 years was 17% for RIC and 14.8% for MAC. This resulted in a 2-year relapse-free survival of 62.4% for RIC and 58.3% for MAC.

In a multivariate analysis for overall survival, RIC resulted in a significant survival benefit at 2 years, the researchers wrote. The 2-year overall survival was 76% for RIC and 63% for MAC.

Improved survival after RIC might be a result of lower mortality after relapse, they added. Whereas after MAC six of nine patients who experienced relapse died, in the RIC arm, only two of 11 patients who experienced relapse died.

In the low-risk group, treatment with RIC resulted in a lower non-relapse mortality (HR, 0.30). However, in patients with intermediate- and high-risk disease, treatment with RIC resulted in a higher non-relapse mortality (HR, 1.17; and HR, 2.14). The researchers noted that conclusive answer for this observation cannot be given, but a possible explanation would be that low-risk patients are protected from relapse and are thus more at risk for death without relapse.

Acute grade 2 to grade 4 and grade 3 and 4 graft-vs-host disease occurred in 32.3% and 15% of patients in the RIC arm and 37.5% and 14% of patients in the MAC arm, respectively. The cumulative incidence of chronic graft-vs-host disease was 61.6% after RIC and 64.7% after MAC.

The researchers concluded by writing, our study shows that RIC and MAC followed by allogeneic stem-cell transplantation resulted in at least an equivalent survival trend for a better 2-year overall survival, especially in the cytogenetic low-risk group, suggesting that RIC can be offered as an alternative to a myeloablative regimen.

Read more from the original source:
Survival in MDS Equivalent With Reduced-Intensity Conditioning - Cancer Network

Duluth Woman Meets, Finds Similarities with Stem Cell Donor – WDIO-TV

So how did they come together? It was less than 3 years ago that Edwards received the toughest news anyone can receive from a doctor.

"I was then diagnosed with leukemia, a rare form of leukemia," said Edwards.

The treatment for this rare form of blood cancer included multiple rounds of chemotherapy and radiation.

"All in all, it was enough toxins to kill a person if you ask me," said Edwards.

Edwards was also hoping to find help from someone else's blood.

"We started the search through Delete Blood Cancer and found a match," said Edwards.

The goal was to find a donor with a similar genetic makeup who could give Edwards their stem cells.

"We tried to match my brother and sister, but unfortunately there were not. So, we kept the search until we could find a match. It was a little nerve-racking, said Edwards.

That's where Halfkann comes in.

"I got a letter that I can be a stem cell donor, and I must go to the clinic in Cologne," said Halfkann.

Halfkann was already previously registered having signed up after one of her coworkers became ill. Although no successful matches were found back in Germany, in Minnesota, Halfkann was exactly who Merissa was looking for.

"Daniela is the only match in the world," said Edwards.

The news that Halfkann could save a stranger's life in the United States delighted the soft-spoken German.

"I'm so happy. I'm grateful," said Halfkann.

The stem cell procedure was pretty simple. Daniela donated blood. The stem cells were filtered out, then sent to Merissa in Minnesota where they were injected.

"There's a lot of complications after the stem cell transplant that could've gone wrong. Fortunately it didn't, which made Daniela an even more perfect match than she already is," said Edwards.

When Edwards heard about the woman who extended her life, she connected with Halfkann online.

"At first we wrote email, and then we connected on Facebook," said Halfkann.

After just a few notes, it was quickly discovered that the two have more in common than the blood running through their veins.

"We like a lot of the same things. Both have 2 children. Both of our husbands are firefighters," said Edwards.

And Edwards continues to successfully battle cancer.

"Right now I am in remission. That doesn't mean that I'll necessarily be cancer-free, but knock on wood...that's the goal...that the cancer will never come back," said Edwards.

There was only one thing left for Edwards to do; meet the woman and family that saved her life. So just a few weeks ago, the pair met for the very first time at Duluth International Airport.

"She is so nice. She is so lovely. I'm so happy we can be here," said Halfkann.

In the ten days together, they and their families created many memories. Halfkann got a glimpse of the life Edwards is now able to hold on to, and it wasn't long before the pair found more in common.

"We seem to like the same things...fruity tea, crafting, sewing, just similar interests in hobbies. Another common interest, shoes," said Edwards.

Both husbands also enjoyed their time together. At the firehouse, Merissa's husband, Dennis, giving Daniela's husband, Stefan, a tour of some of the American rigs and a ride along during an emergency call.

Back at headquarters, the crew made a home-cooked dinner for Halfkann's family and someone else who helped make all of this happen: Amanda Schamper, a representative of DKMS, the registry that matched Edwards and Halfkann.

"What we try to do is to raise awareness in all communities that this is a problem out there. People are searching for their donor match and can't find one," Schamper.

Schamper also showed everyone just how easy it is to sign up to be a bone marrow and stem cell donor.

"We do have a statistic that nearly 14,000 patients are told that they needed a transplant each year, and less than half can't get one because they can't find a donor match on the registry, said Schamper.

During the visit, Edward's extended family threw a get-together in honor of Halfkann. Edward's sister-in-law Kris Hansen is just as grateful.

"Just to know that she's here and they've met each other, and that she can save a life...it's incredible. It's nice to be able to see her and her family and her two adorable daughters," said Hansen.

Through the countless hugs at the party, family members repeated one phrase that transcends all languages.

"I guess the biggest thing we have to say is Danka Daniella!" said Hansen.

"Thank you for saving my life. Thank you for letting me be a Mom. Thank you for coming here so I can meet you and meet your beautiful children and your husband," Edwards said to Halfkann.

And with thanks, comes gratitude.

"I'll forever be grateful to you. You will always be a part of my family." said Edwards.

And this bond that will last a lifetime.

"We're forever connected," said Edwards.

"Yes. Forever," said Halfkann.

Edwards says she and her family are making plans to visit the Halfkann's in Germany.

If you're interested in signing up to become a bone marrow or stem cell donor, it's free and only takes a few moments. A link to that website can be found here.

Read the original:
Duluth Woman Meets, Finds Similarities with Stem Cell Donor - WDIO-TV